Bagwell C B, Clark G M, Spyratos F, Chassevent A, Bendahl P O, Stål O, Killander D, Jourdan M L, Romain S, Hunsberger B, Wright S, Baldetorp B
Verity Software House, Inc., Topsham, Maine, USA.
Clin Lab Med. 2001 Dec;21(4):875-95, x.
Both DNA ploidy and S-phase ploidy are promising prognostic factors for node-negative breast cancer patients. Based largely on the analysis of one large study, much of the reported problems with these factors have been caused by some unappreciated complexities in categorizing DNA ploidy into low- and high-risk groups and the lack of some necessary adjustments to eliminate unwanted correlations between DNA S-phase and ploidy. When both DNA ploidy and S-phase are compensated properly, they become independent prognostic markers, forming a powerful prognostic model.
DNA倍体和S期倍体都是淋巴结阴性乳腺癌患者很有前景的预后因素。很大程度上基于一项大型研究的分析，关于这些因素所报道的许多问题是由于在将DNA倍体分类为低风险和高风险组时存在一些未被认识到的复杂性，以及缺乏一些必要的调整来消除DNA S期和倍体之间不必要的相关性。当DNA倍体和S期都得到适当补偿时，它们就会成为独立的预后标志物，形成一个强大的预后模型。
